SYRE short interest
Spyre Therapeutics Inc. · Healthcare · Biotechnology · settlement date 2026-09-30
| Shares short | 12,844,608 |
|---|---|
| Change vs prior report | 715,165 (+5.9%) |
| Change over six months | +23.1% |
| Days to cover | 8.89 (sector: 3.78) |
| Average daily volume | 1,444,056 |
| Rank in Healthcare | #154 of 922 by days to cover |
SYRE short interest, last 12 months
| Settlement | Shares short | Change | Days to cover | Avg daily volume |
|---|---|---|---|---|
| 2026-09-30 | 12,844,608 | +5.9% | 8.89 | 1,444,056 |
| 2026-09-15 | 12,129,443 | +2.3% | 11.58 | 1,047,388 |
| 2026-08-31 | 11,859,975 | +0.9% | 9.69 | 1,223,666 |
| 2026-08-14 | 11,755,434 | -3.2% | 15.95 | 736,817 |
| 2026-07-31 | 12,143,879 | -2.9% | 13.52 | 898,547 |
| 2026-07-15 | 12,508,710 | -8.3% | 9.03 | 1,385,250 |
| 2026-06-30 | 13,640,183 | +8.1% | 5.56 | 2,455,257 |
| 2026-06-15 | 12,616,535 | -0.1% | 10.83 | 1,165,484 |
| 2026-05-29 | 12,627,576 | +1.7% | 15.47 | 816,178 |
| 2026-05-15 | 12,417,051 | +1.6% | 10.44 | 1,189,799 |
| 2026-04-30 | 12,221,682 | +4.7% | 10.04 | 1,217,137 |
| 2026-04-15 | 11,672,747 | +11.8% | 7.35 | 1,587,932 |
| 2026-03-31 | 10,435,737 | +4.4% | 11.48 | 909,125 |
| 2026-03-13 | 9,997,086 | +0.1% | 13.99 | 714,840 |
| 2026-02-27 | 9,985,198 | +1.2% | 12.42 | 803,682 |
| 2026-02-13 | 9,862,924 | -1.2% | 14.87 | 663,160 |
| 2026-01-30 | 9,980,496 | -0.9% | 20.29 | 491,985 |
| 2026-01-15 | 10,069,741 | -13.5% | 13.89 | 724,793 |
| 2025-12-31 | 11,636,998 | -1.5% | 14.06 | 827,619 |
| 2025-12-15 | 11,818,159 | +5.9% | 13.87 | 852,169 |
| 2025-11-28 | 11,157,711 | -10.5% | 18.26 | 610,966 |
| 2025-11-14 | 12,464,842 | +0.5% | 20.15 | 618,472 |
| 2025-10-31 | 12,407,305 | -7.3% | 11.89 | 1,043,667 |
| 2025-10-15 | 13,390,470 | -7.4% | 9.19 | 1,456,858 |
| 2025-09-30 | 14,459,688 | +4.9% | 18.19 | 795,084 |
import finzdata as yf
yf.Ticker("SYRE").short_interest # every report since 2017
yf.Client().short_interest(["SYRE"], start="2018-01-01")Healthcare short interest · SYRE price history · Who owns SYRE · All short interest